OXYMETAZOLINE HYDROCHLORIDE

US Approved OTC

First approved in 1964

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H24N2O.ClH
Molecular Weight	296.836
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of OXYMETAZOLINE HYDROCHLORIDE

Structure Search

SMILES

Cl.CC1=CC(=C(O)C(C)=C1CC2=NCCN2)C(C)(C)C

InChI

InChIKey=BEEDODBODQVSIM-UHFFFAOYSA-N

InChI=1S/C16H24N2O.ClH/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14;/h8,19H,6-7,9H2,1-5H3,(H,17,18);1H

HIDE SMILES / InChI

Molecular Formula	C16H24N2O
Molecular Weight	260.3746
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB00935
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/monograph/oxymetazoline-hydrochloride.html

Oxymetazoline is an adrenergic alpha-agonist, direct acting sympathomimetic, used as a vasoconstrictor to relieve nasal congestion The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis. Oxymetazoline is self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies. Oxymetazoline is available over-the-counter as a topical decongestant in the form of oxymetazoline hydrochloride in nasal sprays such as Afrin, Operil, Dristan, Dimetapp, oxyspray, Facimin, Nasivin, Nostrilla, Sudafed OM, Vicks Sinex, Zicam, SinuFrin, and Mucinex Full Force. Due to its vasoconstricting properties, oxymetazoline is also used to treat nose bleeds and eye redness.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Adrenergic receptor alpha 64 Target ID: CHEMBL2095203 Sources: https://www.drugbank.ca/drugs/DB00935 \| https://www.ncbi.nlm.nih.gov/pubmed/20030735 \| https://www.ncbi.nlm.nih.gov/pubmed/11844675	Agonist 2678	4.96 null [pEC50]
Alpha-2a adrenergic receptor 63 Target ID: CHEMBL1867 Sources: https://www.drugbank.ca/drugs/DB00935 \| https://www.ncbi.nlm.nih.gov/pubmed/24365159 \| https://www.ncbi.nlm.nih.gov/pubmed/1974694	Partial Agonist 290	0.29 nM [Ki]
Serotonin 1a (5-HT1a) receptor 172 Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1678720	Agonist 2678	7.73 null [pEC50]
Serotonin 1d (5-HT1d) receptor 52 Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1678720	Agonist 2678	7.35 null [pEC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Nasal congestion 26 Sources: https://www.drugs.com/ppa/oxymetazoline-nasal.html	Palliative		Approved 8429	Oxymetazoline Hydrochloride Approved Use Temporary relief of nasal congestion (due to a cold, hay fever, or other upper respiratory allergies) and sinus congestion/pressure. Launch Date 1989
Eye irritations 2 Sources: https://www.drugs.com/cdi/oxymetazoline-drops.html	Primary		Approved 8429	OCUCLEAR Approved Use Relief of redness of eye due to minor eye irritations Launch Date 1986

C_max

Value	Dose	Co-administered	Analyte	Population
60.5 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf	20 mg single, topical dose: 20 mg route of administration: Topical experiment type: SINGLE co-administered:		OXYMETAZOLINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.78 ng/mL DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
895 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf	20 mg single, topical dose: 20 mg route of administration: Topical experiment type: SINGLE co-administered:		OXYMETAZOLINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.24 ng × h/mL DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.23 h DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.05 % single, intranasal Dose: 0.05 % Route: intranasal Route: single Dose: 0.05 % Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	unhealthy, 4 years n = 1 Health Status: unhealthy Age Group: 4 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	Other AEs: Hypertensive crisis... Other AEs: Hypertensive crisis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/23679077
1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	Disc. AE: Application site dermatitis, Application site erythema... AEs leading to discontinuation/dose reduction: Application site dermatitis (1.4%) Application site erythema (0.5%) Application site pain (0.5%) Application site dryness (0.2%) Hypoesthesia (0.2%) Paresthesia (0.2%) Rash (0.2%) Urticaria (0.2%) Photosensitivity reaction (0.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
1.5 % 2 times / day multiple, topical Highest studied dose Dose: 1.5 %, 2 times / day Route: topical Route: multiple Dose: 1.5 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29462230	unhealthy, adult Health Status: unhealthy Condition: Erythema Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/29462230	Sources: https://pubmed.ncbi.nlm.nih.gov/29462230

AEs

AE	Significance	Dose	Population
Hypertensive crisis	1 patient	0.05 % single, intranasal Dose: 0.05 % Route: intranasal Route: single Dose: 0.05 % Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	unhealthy, 4 years n = 1 Health Status: unhealthy Age Group: 4 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23679077
Application site dryness	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Hypoesthesia	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Paresthesia	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Photosensitivity reaction	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Rash	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Urticaria	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site erythema	0.5% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site pain	0.5% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site dermatitis	1.4% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 781 substrate 1737	inhibitor 1767 substrate 1037	inhibitor 1852 substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP3A4/5 278	CYP2C19 991 CYP1A2 1054 CYP2B6 664 CYP2C8 693 CYP2C18 138 CYP2E1 667 UGT1A9 380 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A8 283 UGT1A10 291 UGT2B4 249 UGT2B7 389 UGT2B15 203 UGT2B17 213	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2B6 664	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C18 138	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
UGT1A1 418	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A10 291	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A3 422	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A4 347	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A6 307	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A8 283	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B15 203	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B17 213	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B4 249	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B7 389	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A9 380	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	yes
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/; Page: 7.0	yes	no (co-administration study) Comment: concomitant oral moderate CYP2C19 inhibitors (e.g., esomeprazole, fluoxetine, and omeprazole): the results did not indicate an increase in oxymetazoline exposure associated with coadministration of oral moderate CYP2C19 inhibitors Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/; Page: 7.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208552Orig1s000PharmR.pdf#page=19 Page: 19.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7862	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7862
ChemicalBook	CB0371500	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0371500
ZINC	ZINC000000057435	http://zinc15.docking.org/substances/ZINC000000057435
eMolecules	902254	https://www.emolecules.com/cgi-bin/more?vid=902254

PubMed

Title	Date	PubMed
Differential capacities of the RGS1, RGS16 and RGS-GAIP regulators of G protein signaling to enhance alpha2A-adrenoreceptor agonist-stimulated GTPase activity of G(o1)alpha.	2001 Aug	11520900
Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries.	2001 Aug	11481271
Molecular cloning and functional expression of the guinea pig alpha(1a)-adrenoceptor.	2001 Aug 31	11527538
The effect of inferior turbinate hypertrophy on nasal spray distribution to the middle meatus.	2001 Dec	11843929
Presynaptic alpha2-adrenoceptor-mediated modulation of adenosine 5' triphosphate and noradrenaline corelease: differences in canine mesenteric artery and vein.	2001 Feb	11422578
Prejunctional actions of methylenedioxymethamphetamine in vas deferens from wild-type and alpha(2A/D)-adrenoceptor knockout mice.	2001 Jul 6	11448488
Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists.	2001 Jul 6	11331292
Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.	2001 May	11383713
Inhibition of synovial plasma extravasation by preemptive administration of an antiinflammatory irrigation solution in the rat knee.	2001 May	11323366
[Excitatory effect of noradrenaline on rat airway parasympathetic ganglion neurons].	2001 Nov	11774707
Intranasal application of the alpha2-adrenoceptor agonist BHT-920 produces decongestion in the cat.	2001 Nov-Dec	11777250
Renal actions of the alpha2-adrenoceptor agonist, xylazine, in the anaesthetised rat.	2001 Oct	16032189
Vasocontractile effects of alpha 2-adrenergic agonists associated with intracellular calcium release.	2002	12434541
Endothelial inhibitory modulation on the contractile responses to alpha 2-adrenergic agonists.	2002	12434540
Acute exudative inflammation and nasally exhaled nitric oxide are two independent phenomena.	2002 Jan-Feb	11891394
Intracellular sodium modulates the state of protein kinase C phosphorylation of rat proximal tubule Na+,K+-ATPase.	2002 Jun	12028137
Desensitization of alpha(2)-adrenoceptors which regulate noradrenaline synthesis and release after chronic treatment with clorgyline in the rat brain.	2002 May	11901301
Topical nasal anesthesia for transnasal fiberoptic laryngoscopy: a prospective, double-blind, cross-over study.	2003 Apr	12707645
Stimulation of interleukin-12 production in mouse macrophages via activation of p38 mitogen-activated protein kinase by alpha2-adrenoceptor agonists.	2003 Apr 25	12706479
Pharmacological characterization of alpha 2-adrenoceptor-mediated responses in pig nasal mucosa.	2003 Aug	15084187
alpha 2B-Adrenoceptor levels govern agonist and inverse agonist responses in PC12 cells.	2003 Aug 15	12890472
Evidence for the role of alpha1D- and alpha1A-adrenoceptors in contraction of the rat mesenteric artery.	2003 Feb	12646397
5-HT7 receptor-mediated relaxation of the oviduct in nonpregnant proestrus pigs.	2003 Feb 14	12586216
Contractile actions of imidazoline alpha-adrenoceptor agonists and effects of noncompetitive alpha1-adrenoceptor antagonists in human vas deferens.	2003 Feb 21	12591110
Functional characterisation of alpha(1)-adrenoceptors in denervated rat vas deferens.	2003 Jul	12845422
Central serous chorioretinopathy associated with administration of sympathomimetic agents.	2003 Jul	12834690
Alpha 2 adrenoceptor-mediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons.	2003 Mar	12606912
[The use of oxymetazoline in nasal endoscopic sinus surgery].	2003 May	12916356
[Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis].	2003 Oct	14523532
Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.	2003 Sep	14579657
Intranasal drug delivery: an alternative to intravenous administration in selected emergency cases.	2004 Apr	15039670
Behavioral effects of serotonin and serotonin agonists in two crayfish species, Procambarus clarkii and Orconectes rusticus.	2004 Dec	15596395
Construction and analytical applications of plastic membrane electrode for oxymetazoline hydrochloride.	2004 Feb	15055954
The Janus faces of adrenoceptors: factors controlling the coupling of adrenoceptors to multiple signal transduction pathways.	2004 Nov	15566401
Controlling bleeding from superficial wounds by the use of topical alpha adrenoreceptor agonists spray. A randomized, masked, controlled study.	2004 Nov	15488498
Use of mometasone furoate aqueous nasal spray in the treatment of rhinitis medicamentosa: an experimental study.	2005 Apr	15806055
Pulmonary edema following phenylephrine intranasal spray administration during the induction of general anesthesia in a child.	2005 Apr 30	15861508
Differential distribution of functional alph}1-adrenergic receptor subtypes along the rat tail artery.	2005 Aug	15872040
Characterisation of alpha2-adrenoceptor subtypes involved in gastric emptying, gastric motility and gastric mucosal defence.	2005 Dec 28	16313902
Oxymetazoline is equivalent to ciprofloxacin in preventing postoperative otorrhea or tympanostomy tube obstruction.	2005 Feb	15689767
An assessment for the presence of bacterial contamination of Venturi principle atomizers in a clinical setting.	2005 Jan-Feb	15794070
Is oxymetazoline really safe for middle ear use.	2005 Jul	15995530
[Usefulness of fenspiride in the treatment of acute otitis media in children].	2005 Jun	16124370
Otic barotrauma from air travel.	2005 May	15949100
[Investigation of the effect of oxymetazoline on the duration of rhinitis. results of a placebo-controlled double-blind study in patients with acute rhinitis].	2005 Oct 6	16261947
[The observation of the ciliotoxicity of nasal mucosa with nasal decongestant].	2005 Sep	16375111
In situ gelling, bioadhesive nasal inserts for extended drug delivery: in vitro characterization of a new nasal dosage form.	2006 Jan	16213127
Human breast cell lines exhibit functional alpha2-adrenoceptors.	2006 Jul	16292538
Simultaneous determination of triamcinolone acetonide and oxymetazoline hydrochloride in nasal spray formulations by HPLC.	2006 Mar 18	16297589

Patents

Sample Use Guides

In Vivo Use Guide

Pediatric Patients Nasal Congestion Intranasal For self-medication in children ≥6 years of age: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily. Conjunctival Congestion Ophthalmic For self-medication in children ≥6 years of age: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed. Adults Nasal Congestion Intranasal For self-medication: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily. Conjunctival Congestion Ophthalmic For self-medication: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.

Route of Administration: Nasal

In Vitro Use Guide

Oxymetazoline had a concentration-dependent inhibitory effect on cultured human nasal CBF from 0.25 to 2.00 g/L.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:01:54 GMT 2023` Edited by `admin` on `Fri Dec 15 15:01:54 GMT 2023`
Record UNII	K89MJ0S5VY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXYMETAZOLINE HYDROCHLORIDE

Official Name

English

OXYMETAZOLINE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [MART.]

Common Name

English

KOVANAZE COMPONENT OXYMETAZOLINE HYDROCHLORIDE

Brand Name

English

NSC-757254

Code

English

UPNEEQ

Brand Name

English

AGN-199201

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [USP IMPURITY]

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [JAN]

Common Name

English

VISINE L.R.

Brand Name

English

SCH-9384

Code

English

Oxymetazoline hydrochloride [WHO-DD]

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [USAN]

Common Name

English

PHENOL, 3-((4,5-DIHYDRO-1H-IMIDAZOL-2-YL)METHYL)-6-(1,1-DIMETHYLETHYL)-2,4-DIMETHYL-, MONOHYDROCHLORIDE

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [VANDF]

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [MI]

Common Name

English

6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol monohydrochloride

Systematic Name

English

OCUCLEAR

Brand Name

English

OXYMETAZOLINE HCL

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE COMPONENT OF KOVANAZE

Brand Name

English

SCH 9384

Code

English

OXYMETAZOLINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

RHOFADE

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29709